Fig. 7From: LMTK2 binds to kinesin light chains to mediate anterograde axonal transport of cdk5/p35 and LMTK2 levels are reduced in Alzheimer’s disease brainsLMTK2 levels are reduced in post mortem Alzheimer’s disease cortex but not cerebellum. Representative immunoblots showing LMTK2 and NSE levels in post mortem human control (Ctrl) and Alzheimer’s disease cortex and cerebellum. Graphs show quantification of LMTK2 levels in the different samples normalised to NSE levels. Data were analysed by one-way ANOVA and Holm-Sidak post hoc test, error bars are s.e.m., *p < 0.05 **p < 0.01, ns not significantBack to article page